DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate

Information source: Gachon University Gil Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertriglyceridemia

Intervention: placebo (Drug); fenofibrate/omega (Drug); fenofibrate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Gachon University Gil Medical Center

Summary

The investigators hypothesize that fenofibrate/omega will improve insulin resistance compared with fenofibrate

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: flow-mediated dilation

Secondary outcome: insulin resistance

Eligibility

Minimum age: 25 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- hypertriglyceridemia

Exclusion Criteria:

- moderate or severe hypertension, uncontrolled diabetes (HbA1c > 9%), nephrotic

syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease

Locations and Contacts

Gil Medical Center, Incheon 405-760, Korea, Republic of
Additional Information

Starting date: January 2012
Last updated: November 1, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017